Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC113 Dose-Ranging Study for Oral Candidiasis in HIV
NCT00659971Phase 2Completed
- Sponsor
- Pacgen Life Science Corporation
- Start
- Jan 2008
- Primary completion
- Jun 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PAC-113 in oral candidiasis, sponsored by Pacgen Life Science Corporation. Started Jan 2008; status: completed.
02
Drugs
PAC-113
03
Conditions
oral candidiasis
Beyond the preview
Go deeper on NCT00659971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659971.